Lilly’s Omvoh Shows Broad One-Year Disease Control in Ulcerative Colitis and Crohn’s Disease New analyses from Eli Lilly suggest that patients with moderate to severe ulcerative colitis or Crohn’s disease treated with Omvoh, also known as mirikizumab, were able to meet several measures of disease control at the same time after one year of treatment. What the New Analyses Measured In ulcerative colitis, Lilly assessed a composite goal called comprehensive disease control. A pa

The U.S. Food and Drug Administration has granted approval to Roche’s Enspryng, also known as satralizumab, for adults living with thyroid eye disease. With this decision, patients may receive the medicine through an injection under the skin at home, either independently or with help from a trained caregiver. A New Direction for TED Care Thyroid eye disease is an immune-driven disorder linked to thyroid dysfunction. It can lead to inflamed and swollen eye tissues, bulging eye

AbbVie Reports New Skyrizi Intestinal Healing Results From Phase 3 AFFIRM Trial AbbVie has announced additional Phase 3 AFFIRM findings showing higher rates of intestinal healing with subcutaneous Skyrizi (risankizumab) than with placebo in adults with moderately to severely active Crohn’s disease. Higher Healing Rates at Weeks 12 and 24 The latest analysis assessed endoscopic remission and ulcer-free endoscopy. Endoscopic remission measures intestinal inflammation according

Merck's Tulisokibart Produces Strong Mid-Stage Results in Hidradenitis Suppurativa, Setting Up Phase 3 Development Merck has reported positive Phase 2b findings for tulisokibart, an experimental antibody designed to block TL1A, in people with moderate to severe hidradenitis suppurativa. At 16 weeks, two dosing regimens outperformed placebo on the trial's primary measure of clinical response, offering an early signal that a new immune target may have a role in a condition with

Iberdomide Combination Doubles Median Time Without Progression in Phase 3 Myeloma Trial A Bristol Myers Squibb drug combination has reduced the risk of disease progression or death by about half compared with a commonly used regimen in adults with relapsed or refractory multiple myeloma, according to new Phase 3 results. In EXCALIBER-RRMM, patients treated with iberdomide, daratumumab, and dexamethasone had a median progression-free survival of 42 months, compared with 20 mon

The US Food and Drug Administration has approved a new all-oral treatment combination for adults with advanced kidney cancer whose disease has already been treated with PD-1 or PD-L1 immunotherapy. The regimen combines Welireg with Lenvima for renal cell carcinoma containing a clear cell component. The decision provides another treatment option for patients whose cancer has progressed after immune checkpoint therapy. It is also the first FDA-approved regimen to combine an HIF

Johnson & Johnson Reports Lower Early Treatment Burden With Subcutaneous Amivantamab Regimen in EGFR-Mutated Lung Cancer Johnson & Johnson has presented new Phase 2b findings suggesting that a subcutaneous version of its amivantamab-based first-line regimen may reduce several treatment-related challenges for people with advanced EGFR-mutated non-small cell lung cancer. The COPERNICUS study evaluated subcutaneous amivantamab with lazertinib alongside preventive anticoagulation

GSK Bets $750 Million on Chinese Biotech's Triple-Targeting T Cell Engager for Multiple Myeloma, Marking Second Deal in Two Years GSK has agreed to pay up to $750 million for global rights to an experimental cancer immunotherapy from Shanghai-based Chimagen Biosciences. The deal, announced on September 15, 2026, centers on a preclinical trispecific T cell engager designed to treat multiple myeloma, a blood cancer that affects the bone marrow and remains incurable despite rece

AstraZeneca's Tozorakimab Becomes First Biologic to Cut COPD Flare-Ups Across All Patient Types AstraZeneca has released complete data from two late-stage trials showing that its experimental antibody tozorakimab can meaningfully reduce the frequency of dangerous lung flare-ups in patients with chronic obstructive pulmonary disease, even among those who continue to suffer exacerbations despite using standard inhaled medications. What the OBERON and TITANIA Trials Showed The O

Overview of healthcare system Germany maintains near-universal medical protection, insuring roughly 99.9% of its populace through independent, non-profit entities termed sickness funds. Funding relies on mandatory payroll deductions split evenly between workers and employers. Government-backed safety nets guarantee enrollment for job seekers and low-income demographics. With per-capita medical spending ranking among the steepest worldwide, the nation consistently delivers pub

Germany's network of 93 statutory health insurance funds reported a combined surplus of €2.6 billion during the first six months of 2026, a figure that on the surface might suggest the system is back on solid financial footing. But officials and analysts warn that the positive balance sheet masks a deeper structural problem: spending is rising far faster than the contributions that fund the system, and the surplus exists only because insurers raised premiums at the start of t

The Food and Drug Administration granted accelerated approval to Etcamah, known scientifically as camizestrant, for use alongside any of three widely used CDK4/6 inhibitors in adult patients whose tumors carry a particular genetic change called an ESR1 mutation. Why This Approval Matters Breast cancer remains the most frequently diagnosed malignancy among women in the United States, with more than 300,000 new cases identified each year and over 42,000 deaths. The majority of

Regulators in the United States have given the green light to a new spinal injection therapy built to slow one of the rarest and most devastating disorders of the nervous system, handing patients and families their first real treatment option after decades with none. The Food and Drug Administration cleared Zanvastro, known by its scientific name zilganersen, for use in both children and adults living with Alexander disease, a genetic condition so uncommon that it touches rou

Enhertu Combination Approved in EU as First New First-Line Option in a Decade for HER2-Positive Metastatic Breast Cancer The European Commission has approved Enhertu, developed jointly by AstraZeneca and Daiichi Sankyo, in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. This marks the first new first-line treatment approach authorized in the European Union for this patient group in more than ten yea

CRISPR Therapeutics’ CTX310 Shows Durable Lipid Control One Year After Treatment CRISPR Therapeutics presented new one-year follow-up results of investigational gene editing therapy CTX310 produced lasting reductions in a protein linked to cholesterol and triglyceride buildup. A Gene Editing Approach to Lipid Disorders CTX310 is an investigational in vivo CRISPR-Cas9 therapy designed to edit a gene called ANGPTL3 inside liver cells. This gene plays a central role in regulatin

The constitution of India ensures the "right to health" for every citizen. It is the responsibility of the state governments to provide health care services to citizens. The funding for healthcare in India is 3.3% of GDP and is continuously decreasing since (3.75% in 2013). The infant mortality rate was reduced from 88/1,000 in 1990 to 32/1,000 in 2020. The maternal mortality rate was reduced from 556/100,000 to 113/100,000 during 2016-18. Also read: Expected best selling dr

The U.S. Food and Drug Administration has approved MIMRYLO, also known as rusfertide, for the treatment of erythrocytosis in adults with polycythemia vera, a rare and chronic blood cancer. The decision introduces the first hepcidin mimetic medicine authorized for this condition, offering patients a new mechanism of action beyond the therapies currently available. A Long-Standing Challenge in PV Management Polycythemia vera affects an estimated 90,000 people in the United Stat

The U.S. Food and Drug Administration has approved RASONQUE, also known as daraxonrasib, as a once-daily oral treatment for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent chemotherapy. The decision marks the first approval of a broad RAS-targeted medicine for this disease. RASONQUE belongs to a new class of RAS(ON) multi-selective and mutant-selective inhibitors designed to suppre

Rizabutinib: A New Oral Option for Adults with Refractory ITP September 3, 2026 Rizabutinib is approved for adult patients living with persistent or chronic primary immune thrombocytopenic purpura, often shortened to ITP, who have either failed to respond adequately to or cannot tolerate standard treatments such as glucocorticoids and intravenous immunoglobulins. Rizabutinib belongs to a class of drugs known as Bruton's tyrosine kinase inhibitors, or BTK inhibitors, which wor

The U.S. Food and Drug Administration has approved IMAAVY, also known as nipocalimab, for adults and children aged 12 years and older with warm autoimmune hemolytic anemia who are currently receiving or have previously received corticosteroids. The decision gives patients with this rare and potentially life-threatening blood disorder the first treatment specifically approved for warm autoimmune hemolytic anemia. Johnson and Johnson said the approval followed the agency’s prio

Japan Approves Hibsago for Chronic Hepatitis B Japan has cleared GSK’s Hibsago, also known as bepirovirsen, for adults with chronic hepatitis B who have already received at least six months of nucleos(t)ide analogue treatment and meet specified viral-marker criteria. The decision marks the therapy’s first approval anywhere in the world and introduces Japan’s first treatment authorised to pursue a functional cure for chronic hepatitis B. The Ministry of Health, Labour and Welf

MHLW JAPAN | CHUIKYO DRUG PRICING | August 13, 2026 Brand INN Company Dosage Indication Calculated Drug Price Calculation Method and premiums achieved Juxtapid Capsules for Pediatric Use Lomitapide mesylate Recordati Rare Diseases 2mg per capsule Homozygous familial hypercholesterolemia ¥72,127.50 Inter-standard adjustment Child surcharge = 5%, Marvelon Desogestrel / Ethinylestradiol Organon 1 tablet Dysmenorrhea ¥276.90 Similar drug efficacy comparison method (I) Usefulness

Eli Lilly’s Once-Weekly Insulin Efsitora Alfa Gains NICE Support for Type 2 Diabetes NICE has recommended insulin efsitora alfa, developed by Eli Lilly under the brand name Onswik. NICE said clinical evidence indicates that insulin efsitora alfa provides blood glucose control comparable to two established long-acting insulins, insulin degludec and insulin glargine. The weekly medicine could therefore offer patients a less frequent dosing schedule without compromising the leve

The US Food and Drug Administration has cleared Regeneron's Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, marking the second approved treatment for this ultra-rare condition and the first to show meaningful reductions in both new heterotopic ossification lesions and clinician-assessed flare-ups. What changed for FOP patients? Fibrodysplasia ossificans progressiva is a rare genetic disease in which soft tissues such as muscle, tendon and ligament

Merck and Moderna Report Positive Phase 3 Results for Personalized Melanoma Therapy Merck and Moderna have announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene in combination with pembrolizumab as adjuvant treatment for patients with completely resected stage IIB to IV melanoma. The investigational regimen met the study’s primary endpoint of recurrence-free survival and a key secondary endpoint measuring the time patients rema

South Korea’s HIRA to Advise Drugmakers on Faster Rare Disease Listings South Korea’s Health Insurance Review and Assessment Service is preparing a consultation meeting for pharmaceutical companies as part of a pilot program intended to speed up insurance coverage for rare disease treatments. The meeting is designed to help companies understand how the accelerated listing pathway works and how they can apply for coverage for individual products. HIRA and NHIS Join Effort Seve

The National Institute for Health and Care Excellence has supported several new treatment pathways covering hereditary angioedema, mantle cell lymphoma, and chronic lymphocytic leukaemia. The recommendations could expand access to donidalorsen for eligible patients with recurrent hereditary angioedema and introduce two acalabrutinib-based treatment approaches for adults with previously untreated blood cancers. Donidalorsen Recommended for Hereditary Angioedema NICE has recomm

The U.S. Food and Drug Administration has granted accelerated approval to Genglycos, a one-time gene therapy developed by Ultragenyx Pharmaceutical for adults and children aged eight years and older with glycogen storage disease type Ia. The approval makes Genglycos the first FDA-authorized treatment for this rare inherited metabolic disorder. It is also designed to address the genetic cause of the disease rather than focusing only on managing its symptoms. What causes glycog

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free survival versus current first-line therapy in patients with HER2-mutant advanced non-squamous non-small cell lung cancer. In parallel, HUTCHMED announced that the SAFFRON trial met both its progression-free and overall survival endpoints for Tagrisso (osimertinib) plus Orpathys (savolit

Rank Brand Indications H1 Revenues (in billions) 2026 Revenues (in billions) 1 Dupixent Atopic dermatitis, Asthma, CRSwNP, Eosinophilic esophagitis, Prurigo nodularis $10.7 2 Skyrizi Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis $10.0 3 Rinvoq Rheumatoid arthritis, Psoriatic arthritis, Atopic dermatitis, Ulcerative colitis, Crohn's disease, Ankylosing spondylitis, nr-axSpA $4.6 4 Tremfya Plaque psoriasis, Psoriatic arthritis, Ulcerative colitis $3

BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025 BEST SELLING CANCER DRUGS 2025 Rank Brand Company Indications Revenues $ billion 1 Keytruda Merck Melanoma, NSCLC, HNSCC, Hodgkin Lymphoma, Urothelial Cancer, RCC, HCC and several other cancers $31.7 2 Darzalex Johnson and Johnson Multiple myeloma $14.5 3 Opdivo Bristol Myers Squibb Melanoma, NSCLC, Hodgkin Lymphoma, Urothelial Cancer, RCC, HCC and several other cancers $10.0 4 Tagrisso AstraZeneca EGFR positive NSCLC $7.2

A new CVS Caremark and Employee Benefit News survey shows that employers are increasingly relying on pharmacy benefit managers to control prescription drug spending, improve access to specialty medicines, and manage the growing cost of GLP-1 treatments. The State of Pharmacy Management Survey found that employers see three major opportunities for pharmacy benefit management: expanding biosimilar use, developing sustainable GLP-1 strategies, and using digital tools to create a

The Saudi Food and Drug Authority has introduced the New Accelerator Program for Drugs in Rare Diseases, known as NADR, to support the development, registration, and faster availability of medicines for rare conditions. The initiative is intended to strengthen cooperation among regulators, researchers, pharmaceutical companies, and innovators while helping eligible patients gain earlier access to promising treatments. Dedicated Framework for Rare Disease Medicines The NADR pr

The Saudi Food and Drug Authority has become the first regulatory agency worldwide to approve iberdomide for adults with relapsed or refractory multiple myeloma. The treatment, marketed as ZENBEXUS, is authorized for use alongside daratumumab and dexamethasone in patients whose disease has returned or no longer responds adequately to earlier treatment. The SFDA announced the decision on August 11, 2026. Approval Based on Phase 3 Evidence The registration was supported by resu

The US Food and Drug Administration has granted accelerated approval to Zenbexus, also known as iberdomide, in combination with daratumumab and hyaluronidase plus dexamethasone for adults with multiple myeloma previously treated with at least one regimen containing both a proteasome inhibitor and an immunomodulatory medicine. The approval is based on findings from the Phase 3 EXCALIBER-RRMM study, which evaluated the Zenbexus combination in patients with relapsed or refractor

Sl No Brand Q1 H1 9M Total 1 Johnson and Johnson $24.1 $49.4 2 Roche $18.8 $45.5 3 Eli Lilly $19.8 $42.8 4 AbbVie $15.0 $32.0 5 AstraZeneca $15.3 $30.7 6 Pfizer $14.4 $29.5 7 Merck $14.3 $29.1 8 Novartis $13.1 $27.5 9 Novo Nordisk $15.2 $27.0 10 Sanofi $12.4 $25.3 The first quarter of 2026 confirmed that GLP-1 drugs are still rewriting the global pharmaceutical revenue rankings. Eli Lilly posted $19.8 billion revenues, the fastest rate among the top 10 companies, driven entir

Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies

AIFA Forms Expert Panels to Support Oncology and Hematology Decision The Italian Medicines Agency has created two specialist advisory groups focused on cancer care and blood-related malignancies. The initiative is designed to strengthen scientific cooperation with Italy’s leading medical societies and provide additional expertise to AIFA’s Scientific and Economic Commission for Medicines and internal departments. Both panels will operate under the coordination of Pierluigi Ru

Ocrelizumab Secures Expanded Approval for Pediatric Multiple Sclerosis Roche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-remitting multiple sclerosis. Patients must weigh at least 40 kilograms to qualify. Pediatric MS is rare but highly inflammatory and can severely affect cognitive and social development. This regulatory green light relies on the Phase III OPERETTA 2 trial, which proved the monoclo

Italy’s pharmaceutical market recorded higher spending in 2025 despite a modest decline in the number of medicine packs dispensed, according to the latest OsMed report from the Italian Medicines Agency. Total pharmaceutical expenditure reached €39.3 billion, representing a 6% increase from 2024. Public funding accounted for €28.4 billion, up 5.8% year over year, and represented 72.2% of total medicine spending and approximately one-fifth of overall public healthcare expenditu

The National Institute for Health and Care Excellence has endorsed acalabrutinib as an additional treatment option for adults newly diagnosed with mantle cell lymphoma or chronic lymphocytic leukaemia in England. The decision could expand access to targeted therapy for hundreds of patients, including approximately 440 people with previously untreated chronic lymphocytic leukaemia. Longer Disease Control in Mantle Cell Lymphoma Mantle cell lymphoma is an uncommon and fast-grow

Top 10 healthcare companies by revenues | 2026 Rank Company Q1 H1 9M 2026 revenues 1 United Health Group $111.7 $223.7 2 CVS Health $100.4 $206.5 3 Cigna Group $68.5 $140.0 4 Centene $49.9 $103.5 5 Elevance Health $49.5 $99.3 6 Humana $39.6 $80.5 7 Kaiser Permanente $34.6 8 HCA Healthcare $19.1 $39.3 9 Molina Healthcare $10.8 $20.4 10 Tenet Healthcare $5.4 $11.0 United Health Group Q1 REVENUES: UnitedHealth Group reported first-quarter 2026 revenues of $111.7 billion, repres

The U.S. Food and Drug Administration has authorized Pluvicto for use with standard hormone blocking regimens in adults with PSMA positive metastatic hormone sensitive prostate cancer. The decision allows clinicians to combine the radioligand therapy with androgen deprivation and androgen receptor pathway inhibitors in patients whose disease is still hormone sensitive, significantly increasing the group eligible for this targeted approach. PSMAddition data underpin the label

AstraZeneca and Daiichi Sankyo have secured European Commission approval for Datroway (datopotamab deruxtecan) as a first-line monotherapy for adult patients diagnosed with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitor treatments. This regulatory milestone follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use. Also read: UK greenlights aficamten: thous

England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug for NHS use. The move follows simultaneous marketing authorisation from the MHRA and a positive recommendation from NICE, paving the way for rapid rollout across the country. What this approval means for patients? Obstructive hypertrophic cardiomyopathy thickens and stiffens the h

UnitedHealth Group is pouring fresh resources into a Tennessee-led effort to bring preventive and chronic care services closer to residents, especially in rural areas. A new $4 million commitment will help grow the University of Tennessee Health Sciences’ health hub network from five sites to 13 by the end of 2027, with the goal of reaching about 200,000 people across the state. What the funding covers? The support comes through the United Health Foundation, paired with techn

The European Commission has officially granted marketing authorization for AbbVie’s RINVOQ (upadacitinib) for the treatment of severe alopecia areata in patients 12 years of age and older. This approval encompasses both the 15 mg and 30 mg once-daily oral dosing regimens, marking a significant expansion for the JAK inhibitor in the autoimmune therapeutic space. The drug is indicated for individuals experiencing significant hair loss, a condition frequently associated with pro

AstraZeneca Pharma India secured a significant regulatory expansion from the Central Drugs Standard Control Organisation (CDSCO) for trastuzumab deruxtecan. The approval covers the 100 mg/5 mL presentation of the drug for use in a neoadjuvant regimen, administered prior to surgical intervention, for adult patients diagnosed with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer. This treatment protocol involves the administration of trastuzumab deruxtecan followed

Johnson & Johnson has finalized its acquisition of Firefly Bio while establishing a major alliance with Sail Biomedicines. These strategic moves strengthen the healthcare giant's presence in precision oncology and next-generation immunology. Firefly Bio Buyout Strengthens Solid Tumor Strategy The finalized purchase of Firefly Bio cost $1 billion in cash, integrating the target firm's proprietary degrader antibody conjugate platform into the corporate pipeline. This technology

The U.S. Food and Drug Administration has granted approval to Otsuka Pharmaceutical for SIMTRIYO (centanafadine), marking the first regulatory clearance for a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) intended for the treatment of attention-deficit/hyperactivity disorder (ADHD). Indicated for pediatric patients aged 6 years and older weighing at least 20kg, as well as adult patients, the medication is formulated as a once-daily, extended-release capsule.